The COVID-19 infection figures continue to rise and with them the fear: How long can regular school operations be maintained? Experts warn of renewed school closings and recommend specific measures.
we have started to provide the documents for our products in an electronic format. These are the Instructions for Use (IFU), the Safety Data Sheets (SDS) and the Certificate of Analysis (CoA). For batches placed on the market after 01 January 2023, you can find our documents on the eIFU portal https://eifu.r-biopharm.com.
In February 2020, R-Biopharm was one of the first diagnostics companies worldwide to launch a test kit for the novel coronavirus SARS-CoV-2. Now, the test has received the CE label and is thus [...]
R-Biopharm AG receives FDA clearance for RIDA®GENE Norovirus GI/GII, a real time RT-PCR assay for the detection and differentiation of norovirus genogroup I (GI) and II (GII)
Mississauga, Canada and Darmstadt, Germany, 15th May 2020 – R-Biopharm AG and Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator, announces the appointment of R-Biopharm [...]